

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8282282

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	PATENT SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
AMNEAL PHARMACEUTICALS LLC	11/14/2023
RECEIVING PARTY DATA	
Name:	TRUIST BANK, AS ADMINISTRATIVE AGENT
Street Address:	3333 PEACHTREE STREET
Internal Address:	N.E., 7TH FLOOR SOUTH TOWER
City:	ATLANTA
State/Country:	GEORGIA
Postal Code:	30326
PROPERTY NUMBERS Total: 10	
Property Type	Number
Application Number:	18122515
Application Number:	17861844
Application Number:	17984001
Application Number:	63453187
Application Number:	29475938
Application Number:	29520806
Application Number:	29520841
Application Number:	18240029
Application Number:	17967332
PCT Number:	US2022036975
CORRESPONDENCE DATA	
Fax Number:	(212)294-4700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2122946635
Email:	dkumar@winston.com
Correspondent Name:	WINSTON & STRAWN LLP - MARY KATHERINE KULBACK
Address Line 1:	35 W. WACKER DRIVE
Address Line 4:	CHICAGO, ILLINOIS 60601-9703

ATTORNEY DOCKET NUMBER:	180364.5 PSA/AMNEAL/ TB
NAME OF SUBMITTER:	MARY KATHERINE KULBACK
SIGNATURE:	/Mary Katherine Kulback/
DATE SIGNED:	11/16/2023
Total Attachments: 5 source=Truist - Amneal - Patent Security Agreement (First Amendment Amneal)_(19288240)_(1)#page1.tif source=Truist - Amneal - Patent Security Agreement (First Amendment Amneal)_(19288240)_(1)#page2.tif source=Truist - Amneal - Patent Security Agreement (First Amendment Amneal)_(19288240)_(1)#page3.tif source=Truist - Amneal - Patent Security Agreement (First Amendment Amneal)_(19288240)_(1)#page4.tif source=Truist - Amneal - Patent Security Agreement (First Amendment Amneal)_(19288240)_(1)#page5.tif	

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT is dated as of November 14, 2023 by Amneal Pharmaceuticals LLC (the “Grantor”), in favor of Truist Bank, in its capacity as administrative agent and collateral agent (in such capacity, the “Collateral Agent”).

W I T N E S S E T H:

WHEREAS, the Grantor is party to that certain ABL Guarantee and Collateral Agreement dated as of June 2, 2022 (as amended, amended and restated, supplemented, refinanced, replaced, extended or otherwise modified from time to time, the “Security Agreement”) in favor of the Collateral Agent, pursuant to which the Grantor is required to execute and deliver this Patent Security Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor hereby agrees with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meanings given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral. As security for the payment or performance when due (whether at stated maturity, by acceleration or otherwise), as the case may be, in full of the Secured Obligations, the Grantor hereby pledges to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, a security interest in all of such Grantor’s right, title, and interest in or to any and all of the following Intellectual Property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Patent Collateral”), including:

- (a) all Patents issued or applied for in the United States, including those listed on Schedule I;
- (b) all provisionals, reissues, extensions, continuations, divisions, continuations-in-part, reexaminations or revisions thereof, and the inventions disclosed or claimed therein, including the right to make, use, import and/or sell the inventions disclosed or claimed therein;
- (c) all claims for, and rights to sue for, past or future infringements of any of the foregoing; and
- (d) all income, royalties, damages and payments now or hereafter due and payable with respect to any of the foregoing, including damages and payments for past or future infringement thereof.

SECTION 3. Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent pursuant to the Security Agreement and the Grantor hereby acknowledges and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Recordation. This Patent Security Agreement has been executed and delivered by the Grantor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The Grantor authorizes and requests that the Commissioner of Patents record this Patent Security Agreement.

SECTION 5. Counterparts. This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Patent Security Agreement by signing and delivering one or more counterparts.

SECTION 6. Governing Law. THIS PATENT SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (EXCEPT FOR CONFLICTS OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION).

[Signature page follows]

IN WITNESS WHEREOF, the Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

GRANTOR:

AMNEAL PHARMACEUTICALS LLC

By: 

Name: Anastasios Konidaris

Title: Executive Vice President and Chief Financial Officer

Schedule I

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
1.	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	United States of America	18/122515-Mar 16, 2023		AMNEAL PHARMACEUTICALS LLC
2.	IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS	United States of America	17/861844-11-Jul-2022		AMNEAL PHARMACEUTICALS LLC
3.	IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS	United States of America	PCT/US22/36975 —13-Jul-2022		AMNEAL PHARMACEUTICALS LLC
4.	COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN	United States of America	17/984001-9-Nov-2022		AMNEAL PHARMACEUTICALS LLC
5.	IMMUNOSUPPRESSIVE DOSAGE FORMS AND METHODS OF	United States of America	63/453187-20-mar-2023		AMNEAL PHARMACEUTICALS LLC

Patent Title		Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
	USE				
6.	Applicator for applying a liquid to a surface	United States of America	29475938 09-Dec-2013	D752287 22-Mar-2016	AMNEAL PHARMACEUTICAL S LLC
7.	Inhalation device	United States of America	29520806 18-Mar-2015	D769439 18-Oct-2016	AMNEAL PHARMACEUTICAL S LLC
8.	Inhalation device	United States of America	29520841 18-Mar-2015	D767114 2016-Sep-20	AMNEAL PHARMACEUTICAL S LLC
9.	Refill Kit for Implantable Pump	United States of America	18/240,029 30-Aug-2023		AMNEAL PHARMACEUTICAL S LLC
10.	LEVODOPA DOSING REGIMEN	United States of America	17/967,332 17-Oct-2022		AMNEAL PHARMACEUTICAL S LLC